ClinicalTrials.gg
CompletedNCT01171898Updated Jun 5, 2026Results posted

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

A Phase 1/2 interventional study of ARN-509 (Phase 1) and ARN-509 (Phase 2) in Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Completed at 15 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
23rd of 70
127 · median 81
Started
2010
the only one that year
Phase 1/2
2 of 70
none open now
Registered
1st of 70
by date
Lead sponsor
9 of 70
Aragon Pharmaceuticals, Inc.

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 23rd largest by enrollment, is the only one that started in 2010, is one of 2 in phase 1/2, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Non-Metastatic
  • Rising PSA
  • Castration-Resistant
  • Treatment-Naive
  • Post-abiraterone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

NON- CRPC

Inclusion Criteria

  1. or cytologically proven prostate cancer with high risk for development of metastases, defined as either a PSA value >=8 ng/mL within the last 3 months or PSA Doubling Time \<=10 months
  2. Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration)
  3. Castrate levels of serum testosterone of less than or equal to 50 ng/dL
  4. (ECOG) performance status of 0-1
  5. A of at least 3 months

Exclusion Criteria

  1. Distant metastases, including CNS and vertebral or meningeal involvement
  2. Prior treatment with MDV3100
  3. Prior treatment with abiraterone
  4. Prior treatment with ketoconazole
  5. Concurrent treatment with medications known to have seizure potential
  6. Concurrent treatment with . If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.
  7. > 450 msec
  8. History of seizure or condition that may predispose to seizure
  9. Evidence of severe or uncontrolled systemic disease or infection

METASTATIC CRPC, TREATMENT-NAIVE

Inclusion Criteria

  1. Histologically or cytologically proven prostate cancer with progressive disease based on either PSA or radiographic progression
  2. Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration)
  3. Castrate levels of serum testosterone of less than or equal to 50 ng/dL
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  5. A life expectancy of at least 3 months

Exclusion Criteria

  1. History of, or current metastases in the brain or untreated spinal cord compression
  2. Prior treatment with MDV3100
  3. Prior treatment with abiraterone
  4. Prior treatment with ketoconazole
  5. Concurrent treatment with medications known to have seizure potential
  6. Concurrent treatment with corticosteroids. If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.
  7. QTc > 450 msec
  8. History of seizure or condition that may predispose to seizure
  9. Evidence of severe or uncontrolled systemic disease or HIV infection

METASTATIC CRPC, CHEMOTHERAPY-NAIVE, POST-ABIRATERONE

Inclusion Criteria

  1. Histologically or cytologically proven prostate cancer with progressive disease based on either PSA or radiographic progression
  2. Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration)
  3. Castrate levels of serum testosterone of less than or equal to 50 ng/dL
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  5. A life expectancy of at least 3 months
  6. Patients must have received a minimum of 6 months of abiraterone treatment prior to disease progression

Exclusion Criteria

  1. History of, or current metastases in the brain or untreated spinal cord compression
  2. Prior treatment with MDV3100
  3. Prior treatment with ketoconazole
  4. Concurrent treatment with medications known to have seizure potential
  5. Concurrent treatment with corticosteroids. If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.
  6. QTc > 450 msec
  7. History of seizure or condition that may predispose to seizure
  8. Evidence of severe or uncontrolled systemic disease or HIV infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Dose Escalation Cohort (Phase 1)

    ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.

    Drug: ARN-509 (Phase 1)

  • Experimental
    Non-metastatic CRPC (Phase 2)

    Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.

    Drug: ARN-509 (Phase 2)

  • Experimental
    Treatment-naive metastatic CRPC (Phase 2)

    Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.

    Drug: ARN-509 (Phase 2)

  • Experimental
    Post-abiraterone metastatic CRPC (Phase 2)

    Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.

    Drug: ARN-509 (Phase 2)

Interventions

  • ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.

  • ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.

06

What researchers measure

Primary outcomes

  1. Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12

    Percentage of participants with \>=50% decrease in PSA compared to baseline were assessed at Week 12. PSA progression was defined by the protocol-specific Prostate Cancer Working Group 2 (PCWG2) criteria: PSA increase greater than or equal to \[\>=\] 25 percent \[%\] and \>=2 nanogram per milliliter \[ng/mL\] above the nadir confirmed \>=3 weeks later; or \>=25% and \>=2 ng/mL above baseline PSA after 12 weeks.

    Time frame: Week 12

Secondary outcomes

  1. Phase 1 and 2: Median Time to PSA Progression

    Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined by the PCWG2 criteria. PCWG2 criteria: For participants who achieved \>=50% decrease from the baseline PSA, assessment of time to disease progression was when the PSA increased 25% and at a minimum of 2 ng/mL above the nadir at 3 or more weeks later. For participants without a PSA decrease, the time for progression was calculated at the time when the PSA progression was \>=25% and \>=2 ng/mL after 12 weeks.

    Time frame: Up to approximately 7 years

  2. Phase 2: Median Metastasis-Free Survival (MFS)

    MFS was defined as the time from the start of treatment until new metastatic lesions were observed on Computed Tomography/ Magnetic Resonance Imaging (CT/MRI) scans or radionuclide bone scans (according to PCWG2 criteria: appearance of \>=2 new lesions, and, for the first reassessment only, a confirmatory scan performed 6 or more weeks later that showed at least 2 or more additional new lesions) or death, whichever occurred first.

    Time frame: Up to approximately 7 years

  3. Phase 1 and 2: Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the radiographic disease progression or death, whichever occurred first. Radiographic progression defined by at least one of the following: a) Soft tissue progression by modified RECIST confirmed on repeat imaging \>= 6 weeks later; b) Progression by bone scans: 1) first bone scan with \>= 2 new lesions compared to baseline observed \<12 weeks from start date and confirmed on a second bone scan \>=6 weeks later that showed \>=2 additional lesions (a total of \>=4 new lesions compared to baseline); or 2) first bone scan with \>=2 new lesions compared to baseline observed \>=12 weeks from start date and the new lesions verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline).

    Time frame: Up to approximately 7 years

  4. Phase 1 and 2: Objective Response Rate

    Objective Response Rate was defined as the percentage of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.0 (RECIST). Where, CR defined as disappearance of all target lesions. Any pathological lymph nodes must had reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions. Confirmed responses were those that persisted on repeat imaging study for at least 4 weeks after initial documentation of response.

    Time frame: Up to approximately 7 years

07

Results

Posted Jul 27, 2018
Limitations and caveats
These results are up to clinical cutoff (CCO) date 31 March 2017.

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)
Started30512521
Completed26321315
Not completed419126
Withdrew: Death0020
Withdrew: Lost to follow-up0111
Withdrew: Withdrawal by subject1463
Withdrew: Terminated by sponsor1000
Withdrew: Ongoing1930
Withdrew: Other1502

Outcome measures

PrimaryPhase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12

Percentage of participants with \>=50% decrease in PSA compared to baseline were assessed at Week 12. PSA progression was defined by the protocol-specific Prostate Cancer Working Group 2 (PCWG2) criteria: PSA increase greater than or equal to \[\>=\] 25 percent \[%\] and \>=2 nanogram per milliliter \[ng/mL\] above the nadir confirmed \>=3 weeks later; or \>=25% and \>=2 ng/mL above baseline PSA after 12 weeks.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 12
Percentage of ParticipantsDose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)
Phase 1 and 2: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) at Week 1247898822
SecondaryPhase 1 and 2: Median Time to PSA Progression

Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined by the PCWG2 criteria. PCWG2 criteria: For participants who achieved \>=50% decrease from the baseline PSA, assessment of time to disease progression was when the PSA increased 25% and at a minimum of 2 ng/mL above the nadir at 3 or more weeks later. For participants without a PSA decrease, the time for progression was calculated at the time when the PSA progression was \>=25% and \>=2 ng/mL after 12 weeks.

Time frame:
Up to approximately 7 years
Reported as:
Median · Months
Phase 1 and 2: Median Time to PSA Progression
MonthsDose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)
Phase 1 and 2: Median Time to PSA Progression4.9 (3.9 to 9.5)24.0 (16.30 to 35.0)16.5 (5.6 to 59.5)3.0 (2.7 to 4.7)
SecondaryPhase 2: Median Metastasis-Free Survival (MFS)

MFS was defined as the time from the start of treatment until new metastatic lesions were observed on Computed Tomography/ Magnetic Resonance Imaging (CT/MRI) scans or radionuclide bone scans (according to PCWG2 criteria: appearance of \>=2 new lesions, and, for the first reassessment only, a confirmatory scan performed 6 or more weeks later that showed at least 2 or more additional new lesions) or death, whichever occurred first.

Time frame:
Up to approximately 7 years
Reported as:
Median · Months
Phase 2: Median Metastasis-Free Survival (MFS)
MonthsCohort 1: Non-metastatic CRPC (Phase 2)
Phase 2: Median Metastasis-Free Survival (MFS)21.6 (11.5 to 40.9)
SecondaryPhase 1 and 2: Progression-free Survival (PFS)

PFS was defined as the time from randomization to the radiographic disease progression or death, whichever occurred first. Radiographic progression defined by at least one of the following: a) Soft tissue progression by modified RECIST confirmed on repeat imaging \>= 6 weeks later; b) Progression by bone scans: 1) first bone scan with \>= 2 new lesions compared to baseline observed \<12 weeks from start date and confirmed on a second bone scan \>=6 weeks later that showed \>=2 additional lesions (a total of \>=4 new lesions compared to baseline); or 2) first bone scan with \>=2 new lesions compared to baseline observed \>=12 weeks from start date and the new lesions verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline).

Time frame:
Up to approximately 7 years
Reported as:
Median · Months
Phase 1 and 2: Progression-free Survival (PFS)
MonthsDose Escalation Cohort (Phase 1)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)
Phase 1 and 2: Progression-free Survival (PFS)16.82 (11.76 to NA)36.37 (16.66 to NA)NA (NA to NA)
SecondaryPhase 1 and 2: Objective Response Rate

Objective Response Rate was defined as the percentage of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.0 (RECIST). Where, CR defined as disappearance of all target lesions. Any pathological lymph nodes must had reduction in short axis to less than 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of the diameters of the target lesions. Confirmed responses were those that persisted on repeat imaging study for at least 4 weeks after initial documentation of response.

Time frame:
Up to approximately 7 years
Reported as:
Number · Percentage of Participants
Phase 1 and 2: Objective Response Rate
Percentage of ParticipantsDose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)
Phase 1 and 2: Objective Response Rate20 (2.52 to 55.61)0 (0 to 97.50)50 (15.70 to 84.30)0 (0 to 30.85)

Adverse events

Collected over Up to approximately 7 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation Cohort (Phase 1)0/30 (0%)7/30 (23.3%)29/30 (96.7%)
Cohort 1: Non-metastatic CRPC (Phase 2)0/51 (0%)16/51 (31.4%)49/51 (96.1%)
Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)2/25 (8%)10/25 (40%)25/25 (100%)
Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)0/21 (0%)6/21 (28.6%)21/21 (100%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventDose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)
ConstipationGastrointestinal disorders0/300/511/252/21
Back PainMusculoskeletal and connective tissue disorders0/300/510/252/21
AnaemiaBlood and lymphatic system disorders0/301/510/251/21
Food PoisoningGastrointestinal disorders0/300/510/251/21
HypocalcaemiaMetabolism and nutrition disorders0/300/510/251/21
Spinal Cord CompressionNervous system disorders0/300/511/251/21
SyncopeNervous system disorders0/300/510/251/21
HaematuriaRenal and urinary disorders0/301/510/251/21
Urinary RetentionRenal and urinary disorders0/302/510/251/21
Cardiac Failure CongestiveCardiac disorders0/301/511/250/21
Most frequent other events
Showing 10 of 109
Most frequent other events
EventDose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)
FatigueGeneral disorders16/3034/5115/2511/21
NauseaGastrointestinal disorders9/3020/5114/257/21
Abdominal PainGastrointestinal disorders7/3010/5112/251/21
DiarrhoeaGastrointestinal disorders9/3022/5111/258/21
Back PainMusculoskeletal and connective tissue disorders12/3014/516/254/21
ConstipationGastrointestinal disorders10/309/513/254/21
ArthralgiaMusculoskeletal and connective tissue disorders10/3012/517/256/21
Musculoskeletal PainMusculoskeletal and connective tissue disorders7/305/512/256/21
Musculoskeletal Chest PainMusculoskeletal and connective tissue disorders3/302/517/253/21
DyspnoeaRespiratory, thoracic and mediastinal disorders7/304/517/253/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)Total
Mean67.7 ± 9.4472.8 ± 8.7370 ± 11.867.4 ± 9.2870.2 ± 9.82
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)Total
Female00000
Male30512521127
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)Total
Hispanic or Latino12003
Not Hispanic or Latino29492521124
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)Total
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American03025
White30472519121
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Dose Escalation Cohort (Phase 1)Cohort 1: Non-metastatic CRPC (Phase 2)Cohort 2: Treatment-naive Metastatic CRPC (Phase 2)Cohort 3: Post-Abiraterone Metastatic CRPC (Phase 2)Total
United States30512521127
08

Study locations

15 sites
  • San Diego, California, United States
  • San Francisco, California, United States
  • Atlanta, Georgia, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Raleigh, North Carolina, United States
  • Portland, Oregon, United States
  • Lancaster, Pennsylvania, United States
  • Myrtle Beach, South Carolina, United States
  • Dallas, Texas, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
09

References and documents

Publications

  • Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283. PubMed 28633425 ↗
  • Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6. PubMed 27160947 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2010 to primary completion in Aug 2012, 24 months.

Results were first posted in Jul 2018, 5 years 11 months after primary completion. A results delay was requested in Jan 2014.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's 24 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2010
First posted
Jul 29, 2010
StartActual
Jul 26, 2010
Primary completionActual
Aug 20, 2012
CompletionActual
Jul 22, 2025
Results delay requested
Jan 24, 2014
Results first posted
Jul 27, 2018
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01171898
Responsible party
Sponsor
First posted
Jul 29, 2010
Start date
Jul 26, 2010
Primary completion
Aug 20, 2012
Completion
Jul 22, 2025
Results posted
Jul 27, 2018
Last update
Jun 5, 2026

Study contacts

Aragon Pharmaceuticals, Inc Clinical Trial
study director · Aragon Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion